Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
GDF5 Antibody (N-term)
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, WB, E |
|---|---|
| Primary Accession | P43026 |
| Other Accession | NP_000548 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 55395 Da |
| Antigen Region | 13-41 aa |
| Gene ID | 8200 |
|---|---|
| Other Names | Growth/differentiation factor 5, GDF-5, Bone morphogenetic protein 14, BMP-14, Cartilage-derived morphogenetic protein 1, CDMP-1, Lipopolysaccharide-associated protein 4, LAP-4, LPS-associated protein 4, Radotermin, GDF5, BMP14, CDMP1 |
| Target/Specificity | This GDF5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 13-41 amino acids from the N-terminal region of human GDF5. |
| Dilution | WB~~1:1000 IHC-P~~1:10~50 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | GDF5 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | GDF5 |
|---|---|
| Synonyms | BMP14, CDMP1 |
| Function | Growth factor involved in bone and cartilage formation. During cartilage development regulates differentiation of chondrogenic tissue through two pathways. Firstly, positively regulates differentiation of chondrogenic tissue through its binding of high affinity with BMPR1B and of less affinity with BMPR1A, leading to induction of SMAD1-SMAD5-SMAD8 complex phosphorylation and then SMAD protein signaling transduction (PubMed:15530414, PubMed:21976273, PubMed:24098149, PubMed:25092592). Secondly, negatively regulates chondrogenic differentiation through its interaction with NOG (PubMed:21976273). Required to prevent excessive muscle loss upon denervation. This function requires SMAD4 and is mediated by phosphorylated SMAD1/5/8 (By similarity). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). |
| Cellular Location | Secreted. Cell membrane |
| Tissue Location | Predominantly expressed in long bones during embryonic development. Expressed in monocytes (at protein level) |
Provided below are standard protocols that you may find useful for product applications.
Background
GDF5 is a member of the bone morphogenetic protein (BMP) family and the TGF-beta superfamily. This group of proteins is characterized by a polybasic proteolytic processing site which is cleaved to produce a mature protein containing seven conserved cysteine residues. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues. Mutations in this gene are associated with acromesomelic dysplasia, Hunter-Thompson type; brachydactyly, type C; and chondrodysplasia, Grebe type. These associations confirm that the gene product plays a role in skeletal development.
References
Kusafuka, K., et al., Virchows Arch. 442(5):482-490 (2003).
Faiyaz-Ul-Haque, M., et al., Am. J. Med. Genet. 111(1):31-37 (2002).
Everman, D.B., et al., Am. J. Med. Genet. 112(3):291-296 (2002).
Faiyaz-Ul-Haque, M., et al., Clin. Genet. 61(6):454-458 (2002).
Ducy, P., et al., Kidney Int. 57(6):2207-2214 (2000).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
